Replies to post #827 on Idenix Pharmaceuticals (IDIX)

[dewophile]

i concede riba will have to be included in a pivotal trial..and if vx svr is the new threshold to meet idix/nvs may decide to scrap a costly triple combo trial and go straight to protease-polymerase combinations, which SGP would also need if their protease inhibitor is to be measured against a newer higher efficacy standard assuming vx skates through to approval based on their ph 2